Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL6423269 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL15159339 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL319903 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423273 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL12864552 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL289431 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL18926545 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL13840952 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22694307 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100490850-C | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN NINGBO YINGNUO PHARMACE (CN) | 2009-05-27 | — | — | CN | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| CN-1236758-C | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2006-01-18 | — | — | CN | claimed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | claimed |
| US-20240092902-A1 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-LAG3 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | MERCK SHARP & DOHME LLC (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230092707-A1 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | MERCK SHARP & DOHME LLC (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4114863-A1 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | Merck Sharp & Dohme LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3946288-A1 | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOL-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2022-02-09 | — | — | EP | disclosed |
| US-20210363243-A1 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-LAG3 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | US | disclosed |
| WO-2021178611-A1 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | MERCK SHARP & DOHME CORP. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-11052065-B2 | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20040019200-A1 | Cycloalkyl-spiro-1, 2,4,5-tetraoxacyclohexane-spiro-cholic acids and derivatives; antiprotozoa agents, bactericides and antitumor agents | ARMY, UNITED STATES | 2004-01-29 | — | — | US | disclosed |
| CN-1461639-A | Slow-releasing injection contg. hydrocastor oil/medicine (for treatment) solid dispersion microparticle | WANG YUWAN (CN) | 2003-12-17 | — | — | CN | disclosed |
| WO-2003068736-A2 | MIXED STEROIDAL 1,2,4,5-TETRAOXANE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003069303-A2 | ANTIMALARIAL AND ANTIPROLIFERATIVE PHARMACOPHORE MODELS, NOVEL TRYPTANTHRIN COMPOUNDS HAVING INCREASED SOLUBILITY, AND METHODS OF MAKING AND USING THEREOF | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2003-08-21 | — | — | WO | disclosed |
| US-6063396-A | POLYMER MATRIX | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 2000-05-16 | — | — | US | disclosed |
| US-5618553-A | CONTACTING LOCALIZED REGION OF EYE WITH POLYMER IMPLANT HAVING REVERSIBLY ASSOCIATED MODULATING AGENT WHICH IS RELEASED AT RATE SUCH THAT TARGET CELLS ARE PRIMARILY AFFECTED | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1997-04-08 | — | — | US | disclosed |
| US-4198480-A | ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-04-15 | — | — | US | disclosed |
| US-4147778-A | BACTERICIDES, ANTITUMOR, ANTHRACYCLINE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052065-B2 | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist | CD274, PDCD1LG2, PDCD1 | TOP2A 470/4885MEN1 3505/4885THRB 1676/4885 |
| US-20040019200-A1 | Cycloalkyl-spiro-1, 2,4,5-tetraoxacyclohexane-spiro-cholic acids and derivatives; antiprotozoa agents, bactericides and antitumor agents | PKD1, HCCS, POT1 | TOP2A 342/4885MEN1 587/4885THRB 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.